Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ecamsule is an organic compound and a benzylidene camphor derivative used as a sunscreen agent to absorb ultraviolet (UV) light. It is primarily employed in topical formulations to filter out UVA rays (320–400 nm), with some coverage of UVB rays (280–320 nm), providing broad-spectrum photoprotection. Its mechanism involves reversible photoisomerization and photoexcitation upon exposure to UV radiation; the absorbed energy is released as thermal energy without penetrating the skin. This protects against DNA damage such as pyrimidine dimer formation and delays the onset of skin cancer in preclinical models. Ecamsule is highly photostable compared to other UVA filters like avobenzone and does not degrade significantly under sunlight exposure. Developed and patented by L'Oréal, it has been approved for use in Europe since 1991 and by the FDA in 2006 for certain over-the-counter sunscreen products[1][5][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ecamsule.